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Cancer Biology SelectEmerging roles of small RNAs and histone modifications in tumor progression are the topic of this issue’s Cancer Biology
Select. New discoveries are revealing how reduced expression of specific microRNAs promotes tumorigenesis and are
providing insight into themolecular mechanisms that alter patterns of histonemethylation and gene expression in cancer.
In other recent work, microvesicles released from cancer cells are shown to have the capacity to transmit RNA, including
microRNAs, from one cell to another to promote tumor growth.
Prostate Cancer 101
Although the histone methyltransferase EZH2 is overexpressed in multiple solid tumors and con-
tributes to cell proliferation, the basis for its heightened expression is unknown. Varambally et al.
(2008) nowprovide evidence that one factor regulating its expression is amicroRNA,miR-101. The
authors used target prediction tools to assemble a list of 34 candidate microRNAs that might reg-
ulate EZH2 expression. Of these, the expression of only one, miR-101, was found to have a strong
negative correlation with the expression of EZH2 during prostate cancer progression. As further
evidence for a direct regulation of EZH2 by miR-101, the authors show that overexpression of
miR-101 decreased EZH2 expression in cancer cell lines and reduced cell proliferation. Likewise,
EZH2 expression is induced in normal breast epithelia cells by treatment with antagomirs to miR-
101, which block miR-101 function, and antagomir-treated cells exhibit an invasive phenotype.
Through its regulation of EZH2, miR-101 appears to have a major impact on gene expression.
Overexpression of miR-101 in a breast cancer cell line markedly reduced trimethylation of histone
H3 lysine 27 and altered gene expression similar to that observed after knockdown of EZH2. The
authors also conduct genomic analysis in many types of tumors to show that there is strong cor-
relation between miR-101 copy number loss and cancer progression. From these findings, the
authors propose that reintroduction of miR-101 might be therapeutically beneficial. Given that EZH2 is part of the Polycomb
Repressive Complex 2 (PRC2), which has essential roles in maintaining stem cell pluripotency, future work might also explore
whether miR-101 has important roles in embryonic development and normal tissue maintenance.
S. Varambally et al. (2008). Science. Published online November 13, 2008. 10.1126/science.1165395.
A miR Act of Tumor Suppression
ThemiR-15a andmiR16-1microRNAs reside in a region of the genome frequently lost in multiple types of cancer, yet how its
loss contributes to cancer progression is unclear. Bonci et al. (2008) now characterize how the loss of the miRNA loci con-
tributes to multiple stages of prostate cancer progression. miR-15a and miR-16-1 are transcribed as a cluster and share
the same seed region and therefore likely have similar targets. The authors show that expression of the two miRNAs is lost
in 80% of the prostate tumor samples tested. Expression of a transgene that sequestered endogenous miR-15a and
miR-16-1 increased proliferation both in a prostate cancer cell line and in primary prostate cancer cells with normal levels
of miR-15a and miR-16. Likewise, restoration of miR-15a and miR-16-1 in miRNA-defective prostate cancer cells induced
an increase in growth arrest and apoptosis. These findings in vitro are mirrored by in vivo experiments in which nontrans-
formed human prostate cells are made to form tumors in immunodeficient mice as a consequence of knockdown of
miR-15a andmiR-16-1. And the converse experiment is striking—the delivery of a lentiviral vector expressing the twomiRNAs
into prostate tumor xenografts led tomarked tumor regression. In addition to these findings, the authors also expand the list of
known targets for the miRNAs. Prior work has implicated the miRNA cluster in targeting the proapoptotic gene BCL2. The
authors confirm BCL2 as a target in prostate cells and discover two additional targets with oncogenic activity, CCND1 (which
encodes cyclin D1) and WNT3A. These findings suggest that restoring miR-15a and miR-16-1 to prostate cancers in which
they have been lost could be an effective way to simultaneously target many oncogenic activities.
D. Bonci et al. (2008). Nat. Med. 14, 1271–1277.
H3K79 Methylation Leaves Its Mark on Leukemia
According to new work by Krivtsov et al. (2008), changes in histone H3 lysine 79 (H3K79) methyl-
ation are a critical feature of acute lymphoblastic leukemias (ALL) resulting from translocations be-
tween MLL and AF4. Although MLL-AF4 chromosomal translocations are the most common type
of MLL rearrangements identified in human cases of ALL and predict a very poor prognosis, how
the resulting fusion proteins cause disease is incompletely understood. In their current work, Krivt-
sov et al. establish amousemodel of the disease in which the oncogenicMLL-AF4 fusion protein is
expressed conditionally from the endogenous Mll locus. Given that AF4 has been previously
shown to interact with the H3K79methyltransferase DOT1L, the authors examined the distribution
of H3K79 methylation, a histone mark associated with enhanced gene expression, in both the
mouse model and in human cases of MLL-rearranged ALL. In both humans and mice, they
show that MLL-AF4 expression leads to elevation in H3K79 methylation at over 1000 promoters
compared to wild-type cells, and that this change is associated with enhanced gene expression,
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including elevated expression of certain HOX genes. Moreover, this profile is found to distinguish MLL-rearranged ALL from
other types of lymphoblastic leukemia. Diminishment of H3K79 methylation in MLL-AF4-expressing cells with short hairpin
RNAs directed against DOT1L reduced H3K79methylation and diminished expression of HOXA5 and HOXA9. These findings
provide a strong motivation to discover compounds that inhibit DOT1L as a new potential therapeutic approach for the
treatment of ALL caused by MLL-AF4 fusions.
A.V. Krivtsov et al. (2008). Cancer Cell 14, 355–368.
Transformed Cells Get No REST
Although RE1-silencing transcription factor (REST) is a well-known regulator of neu-
ronal differentiation, its emerging role in tumor suppression is less well characterized.
The recent findings of Mulligan et al. (2008) shed light on the mechanism by which
REST represses expression of genes involved in cellular transformation. Their discov-
eries place REST in a complex that contains CDYL (Chromodomain on Y-like) and
G9a, a histone H3 lysine 9 (H3K9) methyltransferase. Further analysis establishes
that CDYL acts as a bridge linking REST and G9a. Knockdown of CDYL with RNAi de-
creases H3K9 dimethylation at REST target genes, although REST occupancy at tar-
get genes is not impaired, suggesting that CDYL has a specific role in mediating H3K9
methylation via G9a recruitment. And, as has been reported previously for knockdown
of REST, knockdown of either CDYL or G9a leads to the transformation of a human
mammary epithelial cell line. Interestingly, transformation does not result from knock-
down of CoREST, a corepressor implicated in REST’s neuronal functions. Hence,
these findings uncover a means by which REST performs one of its multiple biological roles. The authors provide evidence
that transformation may involve derepression of the proto-oncogene TrkC. Future work might also examine the global
changes in gene expression that occur upon disruption of this REST repressor complex.
P. Mulligan et al. (2008). Mol. Cell 32, 718–726.
Glioblastoma Sends Emissaries Bearing
RNAs
The shedding of microvesicles, also known as exosomes, has been ob-
served for multiple cell types and has been implicated in diverse biological
processes, including long-rangemovement ofmorphogens duringDrosoph-
ila development. Skog et al. (2008) have now examined microvesicles
released from human glioblastoma cells to assess their potential capacity
to transfer molecules important for tumor growth from one cell to another.
They report that these microvesicles contain both protein and RNA, and in
subsequent characterization of their RNA content they find both miRNAs
typical of glioblastomas and gene transcripts that could facilitate tumor
growth, including mRNAs for proteins involved in angiogensis. The authors
also provide evidence that mRNA packaged in microvesicles can be trans-
lated in recipient cells. By using purified microvesicles harvested from glio-
blastoma cells transgenically expressing a secreted luciferase from the
copepodGaussia (Gluc), they show thatGlucmRNA can be translated in re-
cipient brain endothelial cells in culture. As evidence that glioblastoma-derived microvesicles could promote angiogenesis,
they show that purifiedmicrovesicles increase tubule growth in an in vitro assay of angiogenesis. These findings also open the
door to analysis of microvesicles for therapeutic purposes, given that microvesicles can be found in serum. As a step in this
direction, the authors show that mRNA for a deletion mutant form of the epidermal growth factor receptor (EGFRvIII), which
defines a subtype of glioma, is detectible in microvesicles obtained from patient serum.
J. Skog et al. (2008). Nat. Cell Biol. Published online November 16, 2008. 10.1038/ncb1800.
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